Research graph
References from BAP1 Loss in Pleural Mesothelioma Is Associated With Reduced Soluble CCL2 in Patient Effusion, Abrogated CCL2-Mediated Monocyte Recruitment In Vitro. Local targets link to admitted publications; unresolved targets remain external evidence.
Immunotherapy approaches for malignant pleural mesothelioma
10.1038/s41571-022-00649-7 · 2022 · External reference
Management of advanced pleural mesothelioma—at the crossroads
10.1200/op.21.00426 · 2022 · External reference
Malignant pleural fluid from mesothelioma has potent biological activities
10.1111/resp.12874 · 2017 · External reference
Profile of soluble factors in pleural effusions predict prognosis in mesothelioma
10.3233/cbm-210280 · 2022 · External reference
Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters
10.1007/s00262-020-02773-8 · 2021 · External reference
BAP1 loss promotes suppressive tumor immune microenvironment via upregulation of PROS1 in Class 2 uveal melanomas
10.3390/cancers14153678 · 2022 · External reference
An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors
10.1158/2159-8290.cd-17-1246 · 2018 · External reference
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
10.1038/s41591-021-01541-0 · 2021 · External reference
BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene × environment interaction with asbestos
10.1073/pnas.2111946118 · 2021 · External reference
BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study
10.1016/j.jtho.2022.04.008 · 2022 · External reference
Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions
10.1002/ijc.2910470219 · 1991 · External reference
Integrative molecular characterization of malignant pleural mesothelioma
10.1158/2159-8290.cd-18-0804 · 2018 · External reference
Robust enumeration of cell subsets from tissue expression profiles
10.1038/nmeth.3337 · 2015 · External reference
TIMER2. 0 for analysis of tumor-infiltrating immune cells
10.1093/nar/gkaa407 · 2020 · External reference
Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma
10.1038/onc.2015.243 · 2016 · External reference
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
10.1136/jitc-2019-000228 · 2020 · External reference
BAP1 deficiency inflames the tumor immune microenvironment and is a candidate biomarker for immunotherapy response in malignant pleural mesothelioma
2024 · External reference
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions
10.1016/j.ebiom.2019.09.003 · 2019 · External reference
Isolated BAP1 genomic alteration in malignant pleural mesothelioma predicts distinct immunogenicity with implications for immunotherapeutic response
10.3390/cancers14225626 · 2022 · External reference
CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions
10.1097/jto.0b013e31824c9272 · 2012 · External reference
Tissue plasminogen activator potently stimulates pleural effusion via a monocyte chemotactic protein-1–dependent mechanism
10.1165/rcmb.2014-0017oc · 2015 · External reference
Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients
10.1186/s12885-019-6419-1 · 2019 · External reference
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma
2013 · External reference
Functional characterisation guides classification of novel BAP1 germline variants
10.1038/s41525-020-00157-6 · 2020 · External reference
CCL2 blockade augments cancer immunotherapy
10.1158/0008-5472.can-09-2326 · 2010 · External reference
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy
10.1038/s42003-020-01441-y · 2020 · External reference
Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer
10.1016/j.jbo.2018.01.002 · 2018 · External reference
